Read related content in the entries on Marketing authorisation under exceptional circumstances of the research pathways.
Specific approval for certain medicines targeting rare diseases or when full data collection is unethical or impossible.
Read related content in the entries on Marketing authorisation under exceptional circumstances of the research pathways.